Sponsor

SRH Wald-Klinikum Gera GmbH

Germany Strasse Des Friedens 122, Debschwitz, 07548 Gera, Germany

About the sponsor

Research activity is centered on unresectable or metastatic melanoma, with particular attention to BRAF V600-mutated disease in inoperable stage III and metastatic stage IV settings.

Advanced melanoma
BRAF-mutated tumors
Metastatic disease

The clinical focus includes patients with large, singular, stable to progressive metastases requiring local intervention alongside systemic treatment.

About Specializations

SRH Wald-Klinikum Gera GmbH runs clinical trials in conditions such as Metastatic malignant melanoma, Malignant melanoma stage IV, Malignant melanoma stage III, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

1 clinical trial

Metastatic malignant melanoma+2

Not recruiting

Registered drugNo placebo

Study of local treatment options for large metastases in patients with BRAF V600 mutated melanoma receiving Encorafenib and Binimetinib combination therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Binimetinib
Sponsor:SRH Wald-Klinikum Gera GmbH

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →